Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
Nicolaus KrögerKatja SockelChristine WolschkeWolfgang BethgeRichard F SchlenkDominik WolfMichael StadlerGuido KobbeGerald Georg WulfGesine BugKerstin Schäfer-EckartChristof ScheidFlorian NolteJan KrönkeMatthias StelljesDietrich Wilhelm BeelenMarion HeinzelmannDetlef HaaseHannes BuchnerGabriele BleckertAristoteles GiagounidisUwe PlatzbeckerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In older patients with MDS, reduced-intensity conditioning HSCT resulted in a significantly improved event-free survival in comparison with continuous 5-aza therapy. Bridging with 5-aza to HSCT before is associated with a considerable rate of dropouts because of progression, mortality, and adverse events.